



Immediate Release

EXPIRY OF OPTIONS

MELBOURNE, Australia, 21 April 2021: Dimerix Limited (ASX: DXB) advises 425,000 unlisted options issued 17 November 2017, have expired. Details of the options are below:

Number of Options	Exercise Price	Expiry Date
425,000 unlisted options	\$0.40	20 April 2021

The capital structure of the Company following the lapse of these options is:

Quoted Securities:

197,999,297 fully paid ordinary shares

Unquoted Securities:

2,117,325 options exercisable at \$0.18 expiring 30 October 2023

2,117,325 options exercisable at \$0.27 expiring 30 October 2023

2,117,325 options exercisable at \$0.36 expiring 30 October 2023

375,000 options exercisable at \$0.18 expiring 31 January 2024

375,000 options exercisable at \$0.27 expiring 31 January 2024

1,750,000 options exercisable at \$0.18 expiring 09 August 2022

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited

Chief Executive Officer

Tel: 1300 813 321

E: investor@dimerix.com

Authorised for lodgement by the Board of the Company

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com



About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) and Acute Respiratory Distress Syndrome (ARDS), and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS). DMX 200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID 19.

About DMX-700

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and life-threatening lung disease. The most common cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke) however, COPD is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma. COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. Moreover, among the top five causes of death globally, this disease is the only one with increasing mortality rates. In 2016, the Global Burden of Disease Study reported a prevalence of 251 million cases of COPD globally, and it was estimated that 3.17 million deaths were caused by the disease in 2015, which equates to 5% of all deaths globally in that year (WHO Factsheet – Chronic Obstructive Pulmonary Disease). The global COPD treatment market was valued at US\$14 billion in 2017 and is projected to increase at a compound annual growth rate of 4.9% to 2026.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com